0QT6 Stock Chart & Stats
€14.40
-€0.62(-4.54%)
At close: 4:00 PM EDT
€14.40
-€0.62(-4.54%)
Day’s Range― - ―
52-Week Range€3.40 - €15.46
Previous CloseN/A
Volume1.58K
Average Volume (3M)45.66K
Market Cap
€437.11M
Enterprise Value€595.85M
Total Cash (Recent Filing)€113.82M
Total Debt (Recent Filing)€179.28M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Apr 08, 2027EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding50,099,620
10 Day Avg. Volume9,051
30 Day Avg. Volume45,664
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside4.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€76.93M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp 2025 revenue rebound indicates that Genfit can generate meaningful commercial or development-related growth in its targeted liver and metabolic disease markets. If the increase is sustained, a larger revenue base could improve operating leverage and support continued investment in its pipeline.
Therapeutic And Diagnostic FocusGenfit’s combination of therapeutic development and diagnostic programs gives the company multiple avenues to address liver-disease needs, including patient identification and stratification. This focused platform may support durable relevance as clinical practice increasingly emphasizes targeted diagnosis and treatment selection.
Prior Cash GenerationPositive operating and free cash flow in 2024 demonstrates that Genfit has previously converted operations into cash, providing evidence of potential financial self-support under more favorable conditions. Repeating that performance would reduce reliance on external funding and strengthen investment capacity.
Bears Say
Negative Equity And Higher DebtThe move to negative equity alongside materially higher debt signals substantial balance-sheet deterioration. It reduces financial flexibility, increases the importance of successful execution and funding access, and leaves less capacity to absorb continued losses or finance development internally.
Renewed Cash BurnA return to negative operating and free cash flow indicates that the business is consuming cash rather than consistently funding itself. Continued burn could pressure liquidity and require additional financing, potentially diverting resources from clinical development and weakening the company’s ability to sustain its programs.
Volatile ProfitabilityThe reversal from positive EBIT, EBITDA, and net income in 2024 to large losses in 2025 shows that earnings are not yet durable. Earlier swings between strong profitability and losses further reduce confidence that revenue growth will translate consistently into sustainable earnings.
Genfit News
0QT6 FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest share price was €3.40 and its highest was €15.46 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is €437.11M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 08, 2027 which is in 163 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 28, 2026. The company reported -€0.2 earnings per share for the quarter, missing the consensus estimate of -€0.16 by -€0.04.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.37.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,099,620 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -€0.2 in its last earnings report, missing expectations of -€0.16. Following the earnings report the stock price went up 9.54%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GB:0QT6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
0QT6 Stock 12 Month Forecast
Average Price Target
€15.00
▲(4.17% Upside)